BBI Solutions has invested in the addition of three new monoclonal antibodies specific for procalcitonin (PCT). Detection of PCT in serum requires high levels of sensitivity to detect small shifts in the ng/mL range. These newly added antibodies have demonstrated detection in multiple matched pair combinations, with greater levels of sensitivity than a current commercially successful pair.

PCT is a protein that is gaining popularity as a reliable biomarker for sepsis. Early detection of sepsis, the inflammatory response triggered by the body’s natural defence against serious bacterial infections, has been shown to improve clinical outcomes.